Navigation Links
Nile Therapeutics Completes Dosing of Phase II Study
Date:7/7/2010

SAN FRANCISCO, July 7 /PRNewswire-FirstCall/ -- Nile Therapeutics, Inc. (Nasdaq: NLTX), a biopharmaceutical company focused on the development of novel therapeutics for cardiovascular disease, today announced that it has completed the dosing of the last patient in NIL-CDNP-CT005, an open-label, single-blind, placebo-controlled Phase II study of CD-NP in patients with acute decompensated heart failure, or ADHF. The study was designed to provide additional information on the safety and tolerability of CD-NP when infused for up to 72 hours in patients with ADHF and mild to moderate renal insufficiency.  Additional endpoints included assessments of symptom relief and effects on biomarkers of heart failure and renal function.  

"We are very pleased with the progress of this trial and look forward to reviewing the final clinical data. We are also very proud and impressed with the hard work of the clinical sites and investigators.  Nile looks forward to building upon these relationships and the experience gained from this trial to optimally design and execute our future studies," said Hsiao D. Lieu, M.D. VP of Clinical Research for Nile.

In total, 77 patients were randomized into six cohorts at one of four doses of CD-NP (1.25, 2.5, 3.75 and 5 ng/kg/min) or placebo. Two cohorts were enrolled at each of the 1.25 and 2.5 ng/kg/min dose levels, which preliminary data suggest are the doses with the most attractive clinical profile to investigate in future ADHF studies.  Over 35% of patients were enrolled in the U.S., with the remaining patients enrolled in Israel and Germany. Nile expects the last
'/>"/>

SOURCE Nile Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
3. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
6. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
7. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
8. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
9. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
10. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
11. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/19/2013)... , May 19, 2013  The non-surgical ... low temperature radiofrequency (RF) energy is effective in ... or reduces the need for medication 10 years ... presented today at the Digestive Disease Week (DDW) ... Florida . "The sustained ...
(Date:5/18/2013)... 2013 Although colonoscopy exams prevent many colon ... sensitive method for detecting colorectal cancers 2 , the ... 3 . EndoChoice ® Inc. today unveiled research ... the accuracy of this procedure and greatly reduces the ... discussing these clinical trial results and featuring the Fuse ...
(Date:5/18/2013)... May 18, 2013 The Open Paradigm ... Occupy Psychiatry , and leading organizations ... announces a social media campaign showcasing video testimonials ... model, which focuses on pathology and illness rather ... the American Psychiatric Association,s (APA) rollout of its ...
Breaking Medicine Technology:Stretta Procedure for GERD: Successful 10 Year Follow-Up Data Presented at Digestive Disease Week--Sustained Improvement, Long-Term Efficacy 2Stretta Procedure for GERD: Successful 10 Year Follow-Up Data Presented at Digestive Disease Week--Sustained Improvement, Long-Term Efficacy 3New Study Shows Full Spectrum Endoscopy Procedure Reduces The 'Miss Rate' of Adenomas During Colonoscopy 2New Study Shows Full Spectrum Endoscopy Procedure Reduces The 'Miss Rate' of Adenomas During Colonoscopy 3New Social Media Campaign Features Stories Of Individuals Who Rejected Psychiatric Diagnoses 2New Social Media Campaign Features Stories Of Individuals Who Rejected Psychiatric Diagnoses 3
(Date:5/19/2013)... Actos lawsuit claims continue ... in U.S. District Court, Western District of Louisiana. ... the Court has modified the litigation’s Bellwether Nomination process, ... than four. The next Status Conference in the federal ... re: Actos Product Liability Litigation, MDL No. 2299) , ...
(Date:5/19/2013)... May 19, 2013 The muscles in ... their functionality and one of the biggest and most ... nervous system. The peripheral system comprises of peripheral nerves ... cord. These nerves ensure that the limbs and hands, ... when these nerves get damaged due to trauma or ...
(Date:5/19/2013)... 19, 2013 Today, Zane Benefits, ... business health insurance . Zane Benefits, which provides ... health benefits, is the leader in health care ... reimbursement arrangements . , According to Zane Benefits’ ... intrinsically know the value of small business health ...
(Date:5/19/2013)... May 19, 2013 Grinding your teeth ... losing sleep, or annoying your spouse. At the same ... CNY Central (“Snoring and Teeth Grinding Could Be a ... teeth grinding can be hard to prevent. Apparently, Obstructive ... and one of its symptoms is a habit of ...
(Date:5/19/2013)... (PRWEB) May 19, 2013 According ... Market Analysis and Forecast (2013 – 2018): By ... Defense, Industrial)); Technology (CCD, CMOS, Contact IS, Infrared, ... of image sensor market was $8.00 billion in ... in 2018, at an estimated CAGR of 3.84% ...
Breaking Medicine News(10 mins):Health News:Actos Lawyers at Bernstein Liebhard LLP Note Issuance of New Case Management Order in Federal Actos Bladder Cancer Litigation 2Health News:Actos Lawyers at Bernstein Liebhard LLP Note Issuance of New Case Management Order in Federal Actos Bladder Cancer Litigation 3Health News:Ultimate Neuropathy Support System Launched by Neuracel - Reaching New Heights in Herbal Medication for Peripheral Neuropathy 2Health News:Zane Benefits Publishes New Information on Small Business Health Insurance 2Health News:Zane Benefits Publishes New Information on Small Business Health Insurance 3Health News:Dr. Kanani, Woodland Hills Dentist: Dangers of Tooth Damage and Obstructive Sleep Disorder 2Health News:Dr. Kanani, Woodland Hills Dentist: Dangers of Tooth Damage and Obstructive Sleep Disorder 3Health News:Image Sensors Market to Reach $10.75 Billion by 2018 at a CAGR of 3.84% - New Report by MarketandMarkets 2Health News:Image Sensors Market to Reach $10.75 Billion by 2018 at a CAGR of 3.84% - New Report by MarketandMarkets 3
... a special supplement, "Evaluation of the American Academy of ... Annals of Family Medicine reports on the results ... medical home concept in primary care practices. ... in 36 diverse U.S. primary care practices, an independent ...
... ... radio listeners on The Penn Project Show that, “The obesity crisis and related problems, such ... America needs to reverse that pro-inflammatory trend with anti-inflammatory diets, such as the Zone Diet." ... New Haven, CT (Vocus) ...
... ... Hispanic families found that untreated tooth decay in mothers almost doubled the odds of tooth ... and their children, the authors say. , ... (Vocus) June 15, 2010 -- A UCSF study examining the oral health of ...
... in wiring previously thought to be fixed , TUESDAY, ... fixed in early life, and circuits in the adult ... study involving mice. , U.S. researchers found that neurons ... alter their relationships with one another after single whiskers ...
... study led by UNC researchers that looks at newly diagnosed lung ... the first to give reasons why patients don,t go to lung ... most profound finding was the fact that African Americans with two ... four out of 100, whereas white patients in the same situation ...
... for those with MRSA in respiratory tract, study shows ... patients with methicillin-resistant staphylococcus aureus (MRSA) in their respiratory ... drug-resistant bacteria, researchers have found. , The new study, ... Journal of the American Medical Association , included 19,833 ...
Cached Medicine News:Health News:Results of first national demonstration project to implement patient-centered medical home released 2Health News:Results of first national demonstration project to implement patient-centered medical home released 3Health News:Results of first national demonstration project to implement patient-centered medical home released 4Health News:Results of first national demonstration project to implement patient-centered medical home released 5Health News:Results of first national demonstration project to implement patient-centered medical home released 6Health News:Results of first national demonstration project to implement patient-centered medical home released 7Health News:Clear Channel's “Penn Project” Features Dr. Barry Sears, Zone Diet Creator, About Obesity in America 2Health News:If Mother Has Tooth Decay, Odds Increase That Child Does Too 2Health News:If Mother Has Tooth Decay, Odds Increase That Child Does Too 3Health News:UNC study helps explain why black patients with lung cancer have surgery less often than whites 2Health News:UNC study helps explain why black patients with lung cancer have surgery less often than whites 3Health News:Drug-Resistant Staph Threatens Cystic Fibrosis Patients 2
Liquichek™ Ethanol/Ammonia Control is a liquid product used to monitor ethanol and ammonia test procedures in the clinical laboratory....
Liquichek Autoimmune Controls are individual controls for monitoring the performance of autoimmune assays....
Lyphochek Assayed Chemistry Control requires no special diluent and has good reconstituted stability for enzymes and CO2. It is assayed for most major instruments and methodologies....
Lyphochek Benzo/TCA Control Set A is ideal for monitoring HPLC methods for identification and quantitation of benzodiazepines and tricyclic antidepressant drugs....
Medicine Products: